Alprostadil (Caverject/MUSE) Geriatric (65+) Safety: What Older Adults and Their Clinicians Need to Know

What Is Alprostadil and Why Is It Used in Older Men?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpora cavernosa and penile arterioles, producing an erection by increasing arterial inflow and restricting venous outflow. It is the first-line second-step therapy for erectile dysfunction (ED) when oral phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil or tadalafil fail or are contraindicated. Two FDA-approved delivery systems exist: Caverject (intracavernosal injection, Pfizer) and MUSE (medicated urethral system for erection, intraurethral pellet). [1]

Erectile dysfunction becomes more prevalent with age. The Massachusetts Male Aging Study found that complete ED affects roughly 5% of men at age 40 and rises to approximately 15% by age 70. [2] Because cardiovascular disease, diabetes, and neurological conditions compound over time, older men are disproportionately represented among those who do not respond to PDE5 inhibitors alone. That makes alprostadil a frequently considered option for men over 65. Age, however, alters how the drug behaves in the body and how safely it can be used.

In the landmark Linet et al. trial published in the New England Journal of Medicine (1996, N=296), intracavernosal alprostadil produced satisfactory erections in approximately 70% of men with refractory ED, including participants with vasculogenic and neurogenic causes. [1] Older men were represented in that cohort, though sub-group analyses by decade were limited. Applying those efficacy data to a geriatric population requires pairing them with an understanding of age-related pharmacokinetic and pharmacodynamic changes.

How Age Changes Alprostadil Pharmacokinetics

Several physiological shifts affect how men over 65 process alprostadil. Renal blood flow declines roughly 1% per year after age 40. [3] Because prostaglandin E1 is rapidly metabolized in the lungs (approximately 80% on a single pass) and subsequently cleared renally, any reduction in glomerular filtration rate (GFR) can extend systemic exposure, raise the risk of hypotension, and increase penile pain. [4]

Hepatic blood flow also drops with age, reducing first-pass metabolism of absorbed drug. Body composition shifts toward higher fat-to-muscle ratios, which may alter distribution. And plasma protein levels, particularly albumin, fall in frail older men, which could increase the free fraction of lipophilic drugs co-administered alongside alprostadil.

For intracavernosal Caverject, systemic absorption from a properly placed injection is low under normal conditions, but injection technique errors are more common in patients with arthritis, tremor, or reduced visual acuity, all of which become more prevalent past age 65. Faulty injection into a vein or subcutaneous tissue increases systemic absorption and the risk of hypotension.

For MUSE, absorption through the urethral mucosa is more variable and systemic exposure tends to be higher than with intracavernosal delivery. A 2001 pharmacokinetic analysis in the Annals of Pharmacotherapy estimated that MUSE can produce plasma alprostadil concentrations six to eight times higher than those achieved with equivalent intracavernosal doses, depending on urethral integrity and co-administered vasodilators. [5] In an older patient already on an angiotensin-converting enzyme (ACE) inhibitor or a calcium channel blocker, that extra systemic load may tip blood pressure into symptomatic hypotensive range.

Starting Dose and Titration Protocol for Geriatric Patients

The Caverject prescribing information specifies that dose titration should begin at 1.25 mcg for neurogenic ED and 2.5 mcg for vasculogenic or psychogenic ED, with upward adjustments of 2.5 to 5 mcg at each supervised visit. [6] For geriatric patients, many urologists and sexual medicine specialists recommend starting at 1.25 mcg regardless of presumed etiology and titrating in increments no larger than 2.5 mcg per visit.

MUSE titration begins at 125 mcg or 250 mcg depending on the patient's prior response to intracavernosal therapy. The American Urological Association's 2018 ED guideline states that all patients receiving their first dose of alprostadil, whether via injection or urethral suppository, should be observed in the clinic for at least 30 minutes post-administration to assess hemodynamic response. [7] For adults over 65 with orthostatic hypotension, polypharmacy, or frailty, extending that observation window to 60 minutes is a reasonable precaution.

The goal is the minimum effective dose that reliably produces an erection lasting 30 to 60 minutes. Exceeding that target dose increases the probability of prolonged erection, penile pain, and fibrosis at injection sites without improving sexual satisfaction.

Hypotension and Cardiovascular Risk

Hypotension is the most clinically significant systemic adverse effect of alprostadil in older adults. Prostaglandin E1 dilates peripheral arterioles, and that effect is additive with antihypertensive agents, nitrates, and alpha-blockers commonly prescribed for benign prostatic hyperplasia (BPH). [8]

One in five men over 65 in the United States takes at least one alpha-blocker. [9] Combining an alpha-blocker such as tamsulosin 0.4 mg with MUSE 500 mcg can produce drops in systolic blood pressure of 20 to 30 mmHg in susceptible individuals. That magnitude of pressure change is enough to provoke a syncopal episode, particularly in men with baseline orthostatic hypotension or those who use the suppository while standing.

The prescribing approach for this combination should include:

1. Measuring sitting and standing blood pressure before the first alprostadil dose.
2. Documenting any current antihypertensive, nitrate, or alpha-blocker therapy.
3. Advising the patient to sit or lie down for 15 minutes after using MUSE and to stand slowly.
4. Considering dose reduction of the alpha-blocker in consultation with the prescribing urologist or internist before initiating MUSE.

The FDA label for Caverject carries no absolute contraindication with antihypertensives, but the 2018 AUA guideline cautions that men on multiple antihypertensive agents represent a higher-risk subgroup requiring hemodynamic monitoring. [7]

Fall Risk and Fracture Prevention

Falls are the leading cause of injury-related death in adults over 65. [10] Any medication that lowers blood pressure or causes vasovagal episodes adds to that risk. Alprostadil does both. Penile pain after injection can provoke a vasovagal response, particularly in men who are needle-averse or who inject in a standing position.

Pre-prescribing fall-risk screening using a validated tool, such as the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm from the CDC, should be part of the intake process for geriatric patients considering alprostadil. [10] Men with a history of one or more falls in the prior 12 months, a Timed Up and Go test result above 12 seconds, or documented orthostatic hypotension may need additional counseling, supervised first-dose administration, and potentially a lower starting dose.

Injection technique training is especially relevant for fall prevention. Teach patients to sit on the edge of the bed or in a firm chair during injection. Attempting self-injection while standing or in a bathroom introduces unnecessary fall risk if a vasovagal event occurs. Written and video-based technique instructions should be provided at the time of training.

Priapism Risk and Emergency Planning in Older Adults

Priapism, defined as an erection lasting more than four hours, is the most serious local adverse effect of alprostadil and requires emergency urological intervention. [6] The risk is dose-dependent and higher at the beginning of therapy before the patient's effective dose is established.

Older men with sickle cell trait, anticoagulant therapy (warfarin, rivaroxaban, apixaban), or antiplatelet therapy (aspirin plus clopidogrel) face a potentially higher bleeding risk if intracorporeal aspiration or sympathomimetic injection is needed to resolve priapism. Approximately 30% of men over 65 are on at least one anticoagulant or antiplatelet agent. [11]

An emergency plan should be documented in the patient chart before alprostadil is dispensed. That plan should name the nearest emergency department with urology coverage available around the clock, provide a written instruction card the patient keeps in their wallet, and specify the four-hour threshold at which they must seek care without waiting. Waiting longer than six hours significantly raises the risk of permanent erectile dysfunction from ischemic damage to cavernosal tissue. [12]

Renal Function Monitoring

Because alprostadil metabolites are cleared renally and because CKD is present in roughly 38% of adults over 65, [3] baseline serum creatinine and estimated GFR (eGFR) should be documented before prescribing. Formal dose-adjustment guidelines specific to alprostadil and CKD stage do not exist in the current FDA label, but clinical consensus among urologists supports starting at the lowest available dose and titrating more slowly (monthly rather than biweekly visits) in men with eGFR <45 mL/min/1.73 m2.

Patients on hemodialysis should be evaluated individually. Prostaglandin E1 clearance during dialysis sessions has not been formally characterized, making dose prediction unreliable. Sexual medicine specialists at academic centers typically manage these cases with direct hemodynamic observation after each dose adjustment.

Drug-Drug Interactions Relevant to Older Adults

Older men often carry a polypharmacy burden. A 2019 analysis in JAMA Internal Medicine found that 42% of adults over 65 take five or more prescription medications simultaneously. [13] Several drug classes interact meaningfully with alprostadil:

Alpha-blockers (tamsulosin, alfuzosin, doxazosin): Additive vasodilation. Risk of symptomatic hypotension. Use the lowest effective alprostadil dose and counsel on positional precautions.

Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers): Additive blood pressure lowering. Beta-blockers also blunt the compensatory tachycardia that normally limits hypotensive drops, making syncope more likely.

Anticoagulants and antiplatelets: No direct pharmacodynamic interaction with alprostadil, but relevant to priapism management. Document INR if the patient is on warfarin; target INR <2.5 before initiating intracavernosal therapy.

Vasoactive drugs used for pulmonary arterial hypertension (sildenafil used off-label, tadalafil, bosentan): Combining PDE5 inhibitors with alprostadil amplifies vasodilation and is generally avoided. If a patient is on a PDE5 inhibitor for pulmonary hypertension rather than ED, alprostadil should be used only under cardiology co-management.

NSAIDs: Prostaglandin E1 synthesis inhibitors may theoretically reduce the pharmacological effect of exogenous PGE1 by altering local tissue receptor dynamics, though this interaction is not well-characterized in clinical trials. Chronic NSAID use in older adults warrants documentation.

Penile Fibrosis and Long-Term Injection Site Complications

Repeated intracavernosal injections carry a cumulative risk of penile fibrosis. The incidence across long-term Caverject users reaches approximately 8 to 11% after two or more years of regular use. [6] Older men with microvascular disease or diabetes may fibrose faster because of impaired tissue repair mechanisms.

Patients should be examined for nodules or plaques at every follow-up visit, typically every 3 to 6 months. Rotation of injection sites to alternating sides of the shaft at each use reduces focal tissue stress. Men who develop palpable plaques should be evaluated for Peyronie's disease, which itself is more prevalent in older age groups.

MUSE avoids the injection-site fibrosis problem but carries its own local adverse effects, principally urethral burning (reported in 12 to 32% of users) and minor urethral bleeding. [14] Men with prior transurethral resection of the prostate (TURP) or urethral stricture disease have higher rates of urethral absorption variability and should use MUSE only with urology guidance.

Deprescribing Considerations and Goals of Care

Alprostadil is a quality-of-life medication, not a life-prolonging therapy. Its continuation depends on the patient's ongoing desire for sexual activity, functional ability to self-administer, partner status, and absence of prohibitive adverse effects. Annual structured reassessment is appropriate for all geriatric users.

A practical deprescribing framework for geriatric alprostadil users includes four checkpoints evaluated at each annual visit:

1. Sexual activity frequency and satisfaction. If the patient reports fewer than two uses per month and no meaningful satisfaction from those encounters, the benefit-risk calculation shifts.
2. Functional status and injection capability. Reduced hand grip strength, vision changes, or new neurological deficits (post-stroke, Parkinson's disease progression) may render safe self-injection impossible. A caregiver cannot legally administer intracavernosal injections in most jurisdictions.
3. Polypharmacy burden change. New additions to the medication list, especially antihypertensives or anticoagulants, should trigger a fresh drug-interaction review.
4. Cardiovascular status. Men who have had a myocardial infarction, unstable angina, or significant arrhythmia in the prior 6 months should pause alprostadil therapy pending cardiology clearance and a Princeton Consensus III assessment of sexual activity readiness. [15]

If any of these checkpoints identifies a concern, a shared decision-making conversation about tapering or stopping alprostadil should be documented in the chart. Stopping alprostadil does not require dose tapering; it can be discontinued abruptly without withdrawal effects.

Patient Education Priorities for Men Over 65

Clear instructions prevent the majority of serious adverse events. At the time of prescribing, document that the following points have been reviewed with the patient and, if present, their partner:

• Inject only into the corpus cavernosum, not into a vein or the glans. Use the 27, 30 gauge, half-inch needle supplied with Caverject.
• Seek emergency care if an erection persists beyond four hours.
• Sit or lie down for 15 minutes after using MUSE. Do not drive immediately after the first dose.
• Refrigerate Caverject vials before mixing; use within 24 hours of reconstitution. Store MUSE in the refrigerator and allow it to reach room temperature before insertion.
• Alternate injection sites each time to reduce fibrosis risk.
• Do not use alprostadil more than three times per week or more than once in a 24-hour period.

Written materials should be provided in a font size appropriate for presbyopia (minimum 14-point). For patients with literacy barriers, pictographic technique guides are available from the manufacturer.

Comparing Caverject and MUSE for the Geriatric Patient

The choice between intracavernosal injection and intraurethral suppository in an older patient depends on dexterity, vascular anatomy, comorbidities, and patient preference. Neither formulation is universally superior.

Caverject produces higher rates of satisfactory erections, with response rates around 70% in refractory ED cohorts. [1] MUSE response rates in similar populations range from 43 to 65% depending on the study and the definition of "satisfactory erection." [14] That efficacy gap may be less clinically meaningful, however, if a patient finds self-injection impossible due to tremor or poor vision.

MUSE carries higher systemic absorption and a greater hypotension risk, but eliminates needle-related anxiety and injection-site complications. For men who live alone, an intraurethral pellet may also be logistically simpler. For men in skilled nursing facilities, MUSE may be more practical because staff can assist without crossing the legal barrier that injection would represent.

The 2018 AUA guideline recommends that the delivery method choice be individualized after a discussion of efficacy, adverse-effect profile, cost, and the patient's manual dexterity. [7] Medicare Part D covers both formulations, though prior authorization requirements vary by plan.

Monitoring Schedule Recommended for Geriatric Alprostadil Users

A structured monitoring schedule reduces adverse events and supports appropriate continuation or stopping decisions:

• First dose: Supervised in-clinic administration with sitting and standing blood pressure measured before dosing and at 15, 30, and 60 minutes post-dosing.
• Month 1 follow-up: Review injection technique, assess for penile pain, fibrosis, or urethral symptoms (MUSE). Document any hypotensive episodes at home.
• Months 3 and 6: Repeat blood pressure check, review polypharmacy list for new additions, assess satisfaction and frequency of use. Check for penile nodules on exam.
• Month 12 and annually thereafter: Complete deprescribing framework assessment (see above), eGFR recheck if CKD present at baseline, review goals of care.

The Princeton Consensus III guidelines note that sexual activity is equivalent in cardiovascular demand to climbing two flights of stairs. [15] For most stable geriatric patients with controlled hypertension or stable coronary artery disease, that level of exertion is acceptable. Men with unstable or uncontrolled cardiovascular disease should not use alprostadil until cardiovascular stabilization is achieved and a cardiologist has cleared them for sexual activity.

Men with eGFR between 30 and 44 mL/min/1.73 m2 should have renal function rechecked every 6 months rather than annually, given the potential for progressive CKD to alter drug handling over time.